Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 12, 2013, Pages 4921-4937

  Zheng, Xiaozhang ^a   Bauer, Paul ^a   Baumeister, Timm ^a   Buckmelter, Alexandre J ^a   Caligiuri, Maureen ^a   Clodfelter, Karl H ^a   Han, Bingsong ^a   Ho, Yen Ching ^a   Kley, Nikolai ^a   Lin, Jian ^a   Reynolds, Dominic J ^a   Sharma, Geeta ^a   Smith, Chase C ^a   Wang, Zhongguo ^a   Dragovich, Peter S ^b   Oh, Angela ^b   Wang, Weiru ^b   Zak, Mark ^b   Gunzner Toste, Janet ^b   Zhao, Guiling ^b   Yuen, Po Wai ^c   Bair, Kenneth W ^a   more..

^a Forma Therapeutics   (United States)

^b GENENTECH INC   (United States)

^c Pharmaron Beijing Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 {8 OXA 3 AZABICYCLO[3.2.1]OCTANE 3 SULFONYL}PHENYL) 3 (PYRIDIN 3 YLMETHYL)UREA; ANTINEOPLASTIC AGENT; CARBAMIC ACID DERIVATIVE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; UNCLASSIFIED DRUG; UREASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BIOCHEMISTRY; CANCER INHIBITION; CATALYSIS; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; LIVER MICROSOME; MOUSE; NONHUMAN; PHARMACOPHORE; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 84879576402     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400186h     Document Type: Article

References (39)

1. Revollo, J. R.; Grimm, A. A.; Imai, S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells J. Biol. Chem. 2004, 279, 50754-50763
2. Galli, M.; Van Gool, F.; Rongvaux, A.; Andris, F.; Leo, O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer Cancer Res. 2010, 70, 8-11
3. Garten, A.; Petzold, S.; Korner, A.; Imai, S.-I.; Kiess, W. Nampt: Linking NAD Biology, Metabolism and Cancer Trends Endocrinol. Metab. 2009, 20, 130-138
4. + metabolism in health and disease Trends Biochem. Sci. 2007, 32, 12-19
5. Zaremba, T.; Ketzer, P.; Cole, M.; Coulthard, S.; Plummer, E. R.; Curtin, N. J. Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines Br. J. Cancer 2009, 101, 256-262
6. Khan, J. A.; Forouhar, F.; Tao, X.; Tong, L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery Expert Opin. Ther. Targets 2007, 11, 695-705
7. Koppenol, W. H.; Bounds, P. L.; Dang, C. V. Otto Warburg's contributions to current concepts of cancer metabolism Nature Rev. Cancer 2011, 11, 325-337
8. Ward, P. S.; Thompson, C. B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate Cancer Cell 2012, 21, 297-308
9. Cerna, D.; Li, H.; Flaherty, S.; Takebe, N.; Coleman, C. N.; Yoo, S. S. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by the small molecule GMX1778 regulates ROS-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner J. Biol. Chem. 2012, 287, 22408-22417
10. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 2009, 324, 1029-1033
11. Biedermann, E.; Hasmann, M.; Loser, R.; Rattel, B.; Reiter, F.; Schein, B.; Seibel, K.; Vogt, K. Preparation and formulation of pyridine derivatives as antitumor agents and immunosuppressants. WO 9748397, 1997.
12. Holen, K.; Saltz, L. B.; Hollywood, E.; Burk, K.; Hanauske, A.-R. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor Invest. New Drugs 2008, 26, 45-51
13. Schou, C.; Ottosen, E. R.; Petersen, H. J.; Bjorkling, F.; Latini, S.; Hjarnaa, P. V.; Bramm, E.; Binderup, L. Novel cyanoguanidines with potent oral antitumor activity Bioorg. Med. Chem. Lett. 1997, 7, 3095-3100
14. Ravaud, A.; Cerny, T.; Terret, C.; Wanders, J.; Bui, B. N.; Hess, D.; Droz, J.-P.; Fumoleau, P.; Twelves, C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3weeks in solid tumours: An ECSG/EORTC study Eur. J. Cancer. 2005, 41, 702-707
15. Hovstadium, P.; Larsson, R.; Jonsson, E.; Skov, T.; Kissmeyer, A.-M.; Krasilnikoff, K.; Bergh, J.; Karlsson, M. O.; Lonnebo, A.; Ahlgren, J. A phase I study of CHS 828 in patients with solid tumor malignancy Clin. Cancer Res. 2002, 8, 2843-2850
16. Galli, U.; Ercolano, E.; Carraro, L.; Blasi Roman, C. R.; Sorba, G.; Canonico, P. L.; Genazzani, A. A.; Tron, G. C.; Billington, R. A. Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage ChemMedChem 2008, 3, 771-779
17. Willardsen, A. J.; Lockman, J. W.; Murphy, B. R.; Judd, W. R.; Kim, I. C.; Kim, S.-H.; Zigar, D. F.; Yager, K. M.; Fleischer, T. C.; Terry-Lorenzo, R. T.; Boniface, J. J.; Parker, D. P.; McAlexander, I. A.; Bursavich, M. G.; Dastrup, D. M. Compounds and therapeutic uses thereof. WO 2011109441, 2011.
18. Lockman, J. W.; Murphy, B. R.; Zigar, D. F.; Judd, W. R.; Slattum, P. M.; Gao, Z.-H.; Ostanin, K.; Green, J.; McKinnon, R.; Terry-Lorenzo, R. T.; Fleischer, T. C.; Boniface, J. J.; Shenderovich, M.; Willardsen, J. A. Analogues of 4-[(7-bromo-2-methyl-4-oxo-3 H -quinazolin-6-yl)methylprop-2-ynylamino]- N -(3-pyridylmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt) J. Med. Chem. 2010, 53, 8734-8746
19. Kumar, D. V.; Slattum, P. M.; Yager, K. M.; Shenderovich, M. D.; Tangallapally, R.; Kim, S. Compounds and therapeutic uses thereof. WO 2012177782, 2012
20. Bernhart, C.; Bouaboula, M.; Casellas, P.; Jegham, S.; Arigon, J.; Combet, R.; Hilairet, S.; Fraisse, P. Nicotinamide derivatives, preparation thereof and therapeutic use thereof. US 20100222319, 2010.
21. Bernhart, C.; Bouaboula, M.; Casellas, P.; Duclos, O.; Bernhart, J. M.; Jegham, S.; McCort, G. Antineoplastic derivatives, preparation thereof, and therapeutic use thereof. WO 2010004198, 2010.
22. Arigon, J.; Bernhart, C.; Bouaboula, M.; Combet, R.; Jegham, S.; Hilairet, S. Anticancer compounds, preparation thereof, and therapeutic use thereof. WO 2010109115, 2010.
23. Arigon, J.; Bernhart, C.; Bouaboula, M.; Combet, R.; Hilairet, S.; Jegham, S. Nicotinamide derivatives, preparation thereof and therapeutic use thereof as anticancer drugs. WO 2010109112, 2010.
24. Arigon, J.; Bernhart, C.; Bouaboula, M.; Dimalta, A.; Nardi, F.; Jegham, S. Nicotinamide derivatives, preparation thereof and therapeutic uses thereof. WO 2012038904, 2012.
25. Arigon, J.; Bernhart, C.; Bosch, M.; Bouaboula, M.; Nardi, F.; Jegham, S.; Combet, R. Thienopyridine nicotinamide derivatives, preparation thereof and therapeutic use thereof. WO 2012038905, 2012.
26. Curtin, M. L.; Sorensen, B. K.; Heyman, H. R.; Clark, R. F.; Woller, K. R.; Shah, O. J.; Michaelides, Mi.; Tse, C.; Vasudevan, A.; Mack, H.; Hansen, T. M.; Sweis, R.; Pliushchev, M. A. Dihydroisoindolecarboxamide derivatives as NAMPT and ROCK inhibitors and their preparation. US 20120122842, 2012
27. Curtin, M. L.; Sorensen, B. K.; Heyman, H. R.; Clark, R. F.; Michaelides, M.; Tse, C. NAMPT inhibitors as therapeutic agents for the treatment of diseases US 20120122924, 2012.
28. Burgos, E. S.; Ho, M.-C.; Almo, S. C.; Schramm, V. L. A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 13748-13753
29. Vajda, S.; Guarnieri, F. Characterization of protein-ligand interaction sites using experimental and computational methods Curr. Opin. Drug Discovery Dev. 2006, 9, 363-369
30. CS-Map distributes solvent like probe molecules over the protein surface, minimizes their energy independently, clusters the resulting probe positions, and ranks the clusters thereby identifying sites where probes consistently bind.
31. Landon, M. R.; Lancia, D. R., Jr.; Yu, J.; Thiel, S. C.; Vajda, S. Identification of hot spots within druggable binding regions by computational solvent mapping of proteins J. Med. Chem. 2007, 50, 1231-1240
32. Khan, J. A.; Tao, X.; Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents Nature Struct. Mol. Biol. 2006, 13, 582-588
33. Takahashi, R.; Nakamura, S.; Nakazawa, T.; Minoura, K.; Yoshida, T.; Nishi, Y.; Kobayashi, Y.; Ohkubo, T. Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase J. Biochem. 2010, 147, 95-107
34. EMolecules Plus screening compound library. http://www.emolecules.com. (Accessed May 2010).
35. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248
36. Rogers, D.; Hahn, M. Extended-connectivity fingerprints J. Chem. Inf. Model. 2010, 50, 742-754
37. + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors Mol. Cell. Biol. 2009, 29, 5872-5888
38. Copeland, R. A. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, 2nd ed.; Wiley-VCH: New York, 2000.
39. The ability of NAM to attenuate the cell potency of Nampt inhibitors has been previously described in the literature: Hasmann, M.; Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis Cancer Res. 2003, 63, 7436-7442